To the editor:

Hepatitis C virus (HCV) is closely related to the development of mixed cryoglobulinemia (MC). Occult HCV infection in sustained virologic responders (SVRs) after antiviral treatment has been shown,1,2  but MC patients have never been investigated.

We studied 102 HCV patients (64 males, mean age 50.8 ± 12.1 years), who were SVRs after interferon-based anti-HCV therapy, consecutively recruited at our Center from July 2003 to July 2004 and followed-up until July 2007. Patients included 13 subjects with MC syndrome (group A, Table 1) and 89 patients without MC (58 males, mean age 50.2 ± 12.5 years; group B). Blood samples were collected at least twice a year.

Table 1

Main clinical and laboratory findings of 13 HCV-positive patients with mixed cryoglobulinemia achieving sustained virological response (group A)

Pt. no.Age at treatment, ySexDurationof MC, yLiver histologic findingsOther clinical featuresCryocrit, %Cryoglobulin compositionRheumatoid factor, IU/mL*
Complement C3/C4 level#
HCV genotypePRE-HCVRNA (serum), IU/mLPosttreatment HCVRNA°
Presence of t(14;18), yes/no
MC syndrome, yes/no
PBMC
UnculturedCultured with mitogens
PREPOSTPREPOSTlymph.macr.PREPOSTPREPOST
54 male Chronic hepatitis Sicca syndrome, peripheral neuropathy IgG+IgM(k) 35 22 64/18 104/18 2c 1.43 × 104 − − no no yes no 
39 male Chronic hepatitis Peripheral neuropathy 1.5 IgG+IgM(k) 57 <20 71/20 111/20 3a 10 × 105 − − yes yes yes yes 
65 female 15 Cirrhosis Peripheral neuropathy, sicca syndrome, renal involvement§ 11 IgG+IgM(k) 107 92 68/1 68/1 2c 1.3 × 106 − yes yes yes yes 
44 female Chronic hepatitis Sicca syndrome, fever IgG+IgM(k) 36 <20 90/13 12718 1b 8 × 105 − yes yes yes yes 
63 female Chronic hepatitis Sicca syndrome IgG+IgM(k) 54 21 125/6 147/21 2c 1.17 × 105 − − − yes no yes no 
50 female 18 Chronic hepatitis Peripheral neuropathy 10 IgG+IgM(k+λ) 289 90 99/16 153/30 2a 9 × 105 − − − yes no yes no 
50 female 15 Chronic hepatitis Peripheral neuropathy IgG+IgM(k) 30 <20 10118 101/25 1b 5.08 × 105 − − no no yes no 
49 male Cirrhosis Peripheral neuropathy, sicca syndrome IgG+IgM(k) 147 27 1252 169/24 1a 1.7 × 104 − − − yes no yes no 
38 male Chronic hepatitis Raynaud phenomenon IgG+IgM(k) 39 <20 121/24 121/24 1a 5.5 × 105 − − yes yes yes yes 
10 32 male Chronic hepatitis Peripheral neuropathy, sicca syndrome IgG+IgM(k+λ) 244 26 8617 107/31 2c 7.5 × 105 − − yes yes yes yes 
11 49 female Chronic hepatitis Sicca syndrome, dermatomyositis IgG+IgM(k) 100 50 138/17 175/32 4c/d 7.47 × 105 − − − yes yes yes yes 
12 41 female Chronic hepatitis Dermatomyositis 1.5 IgG+IgM(k) 40 <20 103/13 110/30 1b 1.4 × 106 − − yes yes yes yes 
13 60 female 11 Chronic hepatitis Peripheral neuropathy, Raynaud phenomenon, renal involvement§ IgG+IgM(k) 4380 130 167/11 148/25 1b 6.5 × 105 − − − no no yes no 
Pt. no.Age at treatment, ySexDurationof MC, yLiver histologic findingsOther clinical featuresCryocrit, %Cryoglobulin compositionRheumatoid factor, IU/mL*
Complement C3/C4 level#
HCV genotypePRE-HCVRNA (serum), IU/mLPosttreatment HCVRNA°
Presence of t(14;18), yes/no
MC syndrome, yes/no
PBMC
UnculturedCultured with mitogens
PREPOSTPREPOSTlymph.macr.PREPOSTPREPOST
54 male Chronic hepatitis Sicca syndrome, peripheral neuropathy IgG+IgM(k) 35 22 64/18 104/18 2c 1.43 × 104 − − no no yes no 
39 male Chronic hepatitis Peripheral neuropathy 1.5 IgG+IgM(k) 57 <20 71/20 111/20 3a 10 × 105 − − yes yes yes yes 
65 female 15 Cirrhosis Peripheral neuropathy, sicca syndrome, renal involvement§ 11 IgG+IgM(k) 107 92 68/1 68/1 2c 1.3 × 106 − yes yes yes yes 
44 female Chronic hepatitis Sicca syndrome, fever IgG+IgM(k) 36 <20 90/13 12718 1b 8 × 105 − yes yes yes yes 
63 female Chronic hepatitis Sicca syndrome IgG+IgM(k) 54 21 125/6 147/21 2c 1.17 × 105 − − − yes no yes no 
50 female 18 Chronic hepatitis Peripheral neuropathy 10 IgG+IgM(k+λ) 289 90 99/16 153/30 2a 9 × 105 − − − yes no yes no 
50 female 15 Chronic hepatitis Peripheral neuropathy IgG+IgM(k) 30 <20 10118 101/25 1b 5.08 × 105 − − no no yes no 
49 male Cirrhosis Peripheral neuropathy, sicca syndrome IgG+IgM(k) 147 27 1252 169/24 1a 1.7 × 104 − − − yes no yes no 
38 male Chronic hepatitis Raynaud phenomenon IgG+IgM(k) 39 <20 121/24 121/24 1a 5.5 × 105 − − yes yes yes yes 
10 32 male Chronic hepatitis Peripheral neuropathy, sicca syndrome IgG+IgM(k+λ) 244 26 8617 107/31 2c 7.5 × 105 − − yes yes yes yes 
11 49 female Chronic hepatitis Sicca syndrome, dermatomyositis IgG+IgM(k) 100 50 138/17 175/32 4c/d 7.47 × 105 − − − yes yes yes yes 
12 41 female Chronic hepatitis Dermatomyositis 1.5 IgG+IgM(k) 40 <20 103/13 110/30 1b 1.4 × 106 − − yes yes yes yes 
13 60 female 11 Chronic hepatitis Peripheral neuropathy, Raynaud phenomenon, renal involvement§ IgG+IgM(k) 4380 130 167/11 148/25 1b 6.5 × 105 − − − no no yes no 

Pt. no. indicates patient number; PRE, pretreatment; POST, posttreatment; lymph., lymphocytes; macr., macrophages; −, negative; and +, positive.

*

Normal value are < 25 UL/mL.

#

Normal values are 83 to 177 mL/dL for complement C3 and 20 to 150 mL/dL for complement C4.

T(14;18) determined in both peripheral blood and bone marrow mononuclear cells.

Other clinical features: MC-related manifestations observed in addition to the classic Meltzer syndrome.

§

Renal involvement was in both cases shown by microscopic hematuria, proteinuria below the nephrotic range (<3 g/24 h), with normal or only fairly reduced renal function (creatinine <1.5 mg%).

Identical N-segments in the pre- and posttreatment samples were observed.

°Posttreatment HCVRNA in serum and liver samples was persistently negative.

Positive-strand and negative-strand (replicative intermediate) HCV RNA was detected by highly sensitive, previously described methods: transcription mediated amplification (TMA; Bayer Healthcare, Tarrytown, NY); reverse transcriptase–polymerase chain reaction [RT-PCR]-nucleic acid-hybridization assay, Real-time PCR, 5′-UTR-HCV RNA negative-strand PCR with Tth polymerase, with appropriate controls.2,3  Peripheral blood mononuclear cells (PBMC) were cultured with mitogens as previously described.2,4  T(14;18) was determined in PBMC by MBR bcl-2/JH PCR as described.5 

In all patients, serum samples were persistently HCV RNA-negative. HCV RNA was repeatedly detected in stimulated cells (mainly lymphocytes) from 12 patients (8 group A, Table 1, and 4 group B; P < .001), whereas posttreatment liver biopsies scored HCV RNA-negative. Negative-strand HCV RNA was shown in PBMC from MC cases.

PBMC infection was shown in 5 patients with persistent MC syndrome and in no subject in whom MC syndrome completely disappeared. Persistence of t(14;18)-positive B-cell clones was associated with persistence of MC syndrome (P = .021; Table 1).

We, and others, previously detected positive- and negative-strand HCV RNA in PBMC, and observed the increased detection of viral sequences after mitogen stimulation.4,6,7  HCV lymphotropism is generally interpreted as a key factor in HCV-related lymphoproliferative disorders, but this hypothesis was never confirmed, probably due to the difficulty in enucleating the role played by lymphatic infection in patients also with liver infection and circulating HCV. In this study, persistence of HCV infection was observed in PBMC (mainly lymphocytes) in the absence of serum or liver HCV-positivity and was significantly associated with MC syndrome. This isolated PBMC infection may be explained by previous data showing that HCV compartmentalization may occur, in which HCV is confined to a given “compartment” not able to “infect” other compartments.8  Of note, serum samples were thoroughly mixed and warmed to resolubilize cryoglobulins before HCV RNA testing.9  Further studies are needed to clarify the mechanisms possibly linking HCV lymphatic infection with MC. The association between persistence of t(14;18) and lymphatic infection and, in turn, between persistence of t(14;18) and MC syndrome add value to the hypothesis of a pathogenetic role also played by t(14;18).

From a clinical point of view, this study emphasizes the relevance of a complete eradication of HCV for the resolution of MC syndrome, even if the presence of (one or more) “point of no return” in the natural history of such lymphoproliferative disorder, with progressive independence from the etiologic agent, cannot be excluded. Actually, cases of persistent syndrome in spite of viral eradication have been described,10  including some personal observations. If this interpretation is correct, the current indication for an early etiologic treatment of HCV-positive MC11  will be clearly reinforced.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Anna Linda Zignego, MD, PhD, Professor of Medicine, Department of Internal Medicine, University of Florence, Viale Morgagni 85 50134 Florence, Italy; e-mail: a.zignego@dmi.unifi.it.

1
Castillo
I
Rodriguez-Inigo
E
Bartolome
J
et al
Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection.
Gut
2005
54
682
685
2
Radkowski
M
Gallegos-Orozco
JF
Jablonska
J
et al
Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.
Hepatology
2005
41
106
114
3
Giannelli
F
Moscarella
S
Giannini
C
et al
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation.
Blood
2003
102
1196
1201
4
Zignego
AL
Macchia
D
Monti
M
et al
Infection of peripheral mononuclear blood cells by hepatitis C virus.
J Hepatol
1992
15
382
386
5
Zignego
AL
Ferri
C
Giannelli
F
et al
Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas.
Ann Intern Med
2002
137
571
580
6
Laskus
T
Radkowski
M
Piasek
A
et al
Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes.
J Infect Dis
2000
181
442
448
7
Zignego
AL
Giannini
C
Monti
M
Gragnani
L
Hepatitis C virus lymphotropism: lessons from a decade of studies.
Dig Liver Dis
2007
39
Suppl 1
S38
S45
8
Ducoulombier
D
Roque-Afonso
AM
Di Liberto
G
et al
Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes.
Hepatology
2004
39
817
825
9
Van Thiel
DH
Fagiuoli
S
Caraceni
P
et al
Cryoglobulinemia: a cause for false negative polymerase chain reaction results in patients with hepatitis C virus positive chronic liver disease.
J Hepatol
1995
22
464
467
10
Levine
JW
Gota
C
Fessler
BJ
Calabrese
LH
Cooper
SM
Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus.
J Rheumatol
2005
32
1164
1167
11
Zignego
AL
Giannini
C
Ferri
C
Hepatitis C virus-related lymphoproliferative disorders: an overview.
World J Gastroenterol
2007
13
2467
2478

Author notes

C.G. and A.P. contributed equally to this work.

Sign in via your Institution